Cite this post as:
Scott Weingart, MD FCCM. Podcast 126 – TTM Trial Right from Niklas Nielsen’s Mouth. EMCrit Blog. Published on June 15, 2014. Accessed on March 24th 2023. Available at [https://emcrit.org/emcrit/ttm-trial-niklas-nielsen/ ].
Financial Disclosures:
Dr. Scott Weingart, Course Director, reports no relevant financial relationships with ineligible companies.
This episode’s speaker(s), (listed above), report no relevant financial relationships with ineligible companies.
CME Review
Original Release: June 15, 2014
Date of Most Recent Review: Jan 1, 2022
Termination Date: Jan 1, 2025
You finished the 'cast,
Now Join EMCrit!
As a member, you can...
- Get CME hours
- Get the On Deeper Reflection Podcast
- Support the show
- Write it off on your taxes or get reimbursed by your department
.
Get the EMCrit Newsletter
If you enjoyed this post, you will almost certainly enjoy our others. Subscribe to our email list to keep informed on all of the Resuscitation and Critical Care goodness.
This Post was by the EMCrit Crew, published 9 years ago. We never spam; we hate spammers! Spammers probably work for the Joint Commission.
Great podcast. No mention though of David Seder’s rebuttal from the neurocritical care conference. I still think there might be something there… in short, treating people with more severe brain injury (by whatever measure you use) with 33. As a cardiologist, my analogy is to ICD. If you had a clinical trial where all people with new heart failure EF 30% were randomized to ICD or no ICD at day zero, it may show no difference. You have to treat the subgroup who’s EF didn’t get better after their ischemia was treated with PCI, and those who get better with… Read more »
the debate will be posted on the site and then we can do an emcritters straw poll
Scott, Thanks so much for doing this, it really has helped answer many of my personal questions and address the concerns issued by the by Dr. Polderman. Despite this, many clinicians seem very resistant to change their targeted temperature after this trial, despite widespread adoption of hypothermia after 2 small RCTs totaling only 300ish patients. This was an excellent study which most everyone agrees on, there was no signal of difference between the two arms (ALL point estimates of benefit favored the 36 group over the 33 group). The St Emlyn’s blog mentions that the ARR varies from 5.4% in… Read more »
yep, ECMO is the ?. Bleeds vs. the desirable lowering of metabolic demand. Need/want a study…